Tiziana Life Sciences Ltd 6-K, filed Nov 9, 2026
Tiziana Life Sciences Ltd (TLSA)
About this 6-K
Tiziana Life Sciences Ltd filed this 6-K on November 9, 2026.
Tiziana Life Sciences will present at BIO-Europe 2026 on November 10, 2026, and host a November 9, 2026 Key Opinion Leader webcast about positive Phase 2a INFORM-MS topline results for intranasal foralumab in na-SPMS. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
November 2026
Commission File Number: 001-38723
Tiziana Life Sciences LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On November 9, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that it will present at BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Tiziana is also hosting a conference call and webcast with Key Opinion Leaders today, Monday, November 9, 2026, at 12:00 p.m. ET / 17:00 GMT, to discuss the positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-286064) and Form S-8 (Reg. No. 333-293620).
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TIZIANA LIFE SCIENCES LTD | |||
| Date: November 9, 2026 | By: | /s/ Keeren Shah | |
| Name: | Keeren Shah | ||
| Title: | Chief Financial Officer | ||
2
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Tiziana Life Sciences LTD Press Release, dated November 9, 2026 |
3
Exhibit 99.1
Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast
BOSTON, MA, November 9, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will present at BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Tiziana is also hosting a conference call and webcast with Key Opinion Leaders today, Monday, November 9, 2026, at 12:00 p.m. ET / 17:00 GMT, to discuss the positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, will deliver a company presentation at BIO-Europe in the Presenting Companies track (Theater A) on Tuesday, November 10, 2026, from 13:45 local time. In addition to the formal presentation, members of the Tiziana management and business development team are attending BIO-Europe and participate in one-to-one partnering meetings. The Company looks forward to engaging with potential strategic partners, investors, and collaborators to discuss the recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), as well as its broader pipeline in neuroinflammatory and neurodegenerative diseases, including Alzheimer’s disease, multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS).
“BIO-Europe is one of the premier global partnering events in our industry, and we are excited to share the progress of our intranasal foralumab program with the international biopharma community,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “Following the positive Phase 2a INFORM-MS data, this is an ideal opportunity to advance discussions on potential collaborations that can help bring this novel therapy to patients with significant unmet needs.”
Reminder: Investor Call with Key Opinion Leaders – Monday, November 9, 2026
As a reminder, Tiziana will host a conference call and webcast with Key Opinion Leaders today, Monday, November 9, 2026, at 12:00 p.m. ET / 17:00 GMT, to discuss the positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS. Sign up to the Webcast here: https://edge.media-server.com/mmc/p/7ox8odig A replay of the call will be available on the Investors section of the Company’s website following the live event.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. Intranasal foralumab is also currently being studied in additional Phase 2 trials in AD, ALS, and MSA.
Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ’seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and statements regarding completion of the INFORM-MS data analysis, presentation of detailed results, engagement with the FDA and potential further clinical development of intranasal foralumab. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul
Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com